The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Afsane Bahrami^{1

2}, Majid Khazaei³, Soodabeh Shahidsales⁴, Seyed Mahdi Hassanian^{5

6}, Malihe Hasanzadeh⁷, Mina Maftouh⁵, Gordon A Ferns⁸, Amir Avan⁵

Affiliations

¹ Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁵ Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁷ Department of Gynecology Oncology, Woman Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁸ Division of Medical Education, Brighton and Sussex Medical School, Falmer, Brighton, Sussex BN1 9PH, UK.

PMID: 28513879
DOI: 10.1002/jcb.26136

Review

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Afsane Bahrami et al. J Cell Biochem. 2018 Jan.

. 2018 Jan;119(1):213-222.

doi: 10.1002/jcb.26136. Epub 2017 Jul 4.

Authors

Afsane Bahrami^{1

2}, Majid Khazaei³, Soodabeh Shahidsales⁴, Seyed Mahdi Hassanian^{5

6}, Malihe Hasanzadeh⁷, Mina Maftouh⁵, Gordon A Ferns⁸, Amir Avan⁵

Affiliations

¹ Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁵ Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁷ Department of Gynecology Oncology, Woman Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
⁸ Division of Medical Education, Brighton and Sussex Medical School, Falmer, Brighton, Sussex BN1 9PH, UK.

PMID: 28513879
DOI: 10.1002/jcb.26136

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213-222, 2018. © 2017 Wiley Periodicals, Inc.

Keywords: BREAST CANCER; EVEROLIMUS; PI3K/Akt/mTOR INHIBITORS.

PubMed Disclaimer

Cited by

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
Tian T, Li X, Zhang J. Tian T, et al. Int J Mol Sci. 2019 Feb 11;20(3):755. doi: 10.3390/ijms20030755. Int J Mol Sci. 2019. PMID: 30754640 Free PMC article. Review.
Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours.
Setargew YFI, Wyllie K, Grant RD, Chitty JL, Cox TR. Setargew YFI, et al. Cancers (Basel). 2021 Jan 27;13(3):491. doi: 10.3390/cancers13030491. Cancers (Basel). 2021. PMID: 33513979 Free PMC article. Review.
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Godoy-Ortiz A, Sanchez-Muñoz A, Chica Parrado MR, Álvarez M, Ribelles N, Rueda Dominguez A, Alba E. Godoy-Ortiz A, et al. Front Oncol. 2019 Oct 29;9:1124. doi: 10.3389/fonc.2019.01124. eCollection 2019. Front Oncol. 2019. PMID: 31737566 Free PMC article. Review.
Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer.
Decker JT, Ma JA, Shea LD, Jeruss JS. Decker JT, et al. Cancers (Basel). 2021 Oct 25;13(21):5343. doi: 10.3390/cancers13215343. Cancers (Basel). 2021. PMID: 34771508 Free PMC article. Review.
Calcium Homeostasis in the Development of Resistant Breast Tumors.
Martin-García D, Téllez T, Redondo M, García-Aranda M. Martin-García D, et al. Cancers (Basel). 2023 May 23;15(11):2872. doi: 10.3390/cancers15112872. Cancers (Basel). 2023. PMID: 37296835 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Affiliations

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous